SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for SNP rs20715592

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 A Biomarker Driven, Open Label, Phase II Study of VEGFR2 Inhibitor Apatinib in Patients With Recurrent or Refractory Advanced Bone and Soft Tissue Sarcoma

The aim of this study is to evaluate the efficacy and safety of Apatinib monotherapy for relapsed or refractory advanced bone and soft tissue sarcoma with VEGFR-2 (KDR) 604A>G polymorphism as predictive biomarker

NCT04072042 Sarcoma Drug: Apatinib monotherapy
MeSH: Sarcoma
HPO: Sarcoma Soft tissue sarcoma

Our preliminary data suggests that rs2071559_VEGFR2 604A>G polymorphism is associated pulmonary tumor cavitation (predisposes one to pneumothorax), hair depigmentation, superior efficacy and less likelihood of extra-pulmonary lesion.

Primary Outcomes

Description: The proportion of patients that are progression-free according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

Measure: progression free rate (PFR)

Time: 4 months from recruitment

Secondary Outcomes

Description: The proportion of patients with negative biomarker that are progression-free according to RECIST 1.1

Measure: progression free rate (PFR) in biomarker negative sub-cohort

Time: 4 months from recruitment

Description: The difference of PFS between biomarker positive and biomarker negative sub-cohorts with log-rank test

Measure: progression free survival(PFS) between biomarker positive and negative sub-cohorts

Time: Baseline until disease progression or death, whichever occurs first, assessed for an average of 8 months

Description: Correlation of KDR 604 AA,AG,GG genotype with the incidence of pulmonary lesion cavitation or pneumothorax among all comers

Measure: Correlation of KDR polymorphism with pulmonary lesion cavitation/pneumothorax

Time: 4 months from recruitment

Description: Correlation of KDR 604 AA,AG,GG genotype with the incidence of hair depigmentation among all comers

Measure: Correlation of KDR polymorphism with hair depigmentation

Time: 4 months from recruitment

Description: Correlation of KDR 604 AA,AG,GG genotype with progression free survival according to RECIST 1.1 among all comers

Measure: Correlation of KDR polymorphism with progression-free survival(PFS)

Time: Baseline until disease progression or death, whichever occurs first, assessed for an average of 8 months

Description: The occurrence of each adverse events(AEs), severe AEs(SAEs) and death according the CTCAE_5.0

Measure: Incidence of Treatment-Emergent Adverse Events

Time: through study completion, an average of 8 months

Description: Correlation of CSF1R (rs10079250) genotype with the incidence of wound complications among all comers

Measure: Correlation of CSF1R polymorphism (rs10079250) with wound complication

Time: through study completion, an average of 8 months

Description: Correlation of PDGFRα (rs35597368) genotype with the incidence of hand foot skin reaction among all comers

Measure: Correlation of PDGFRα polymorphism (rs35597368) with hand foot skin reaction

Time: through study completion, an average of 8 months

Description: to correlate the incidence of targeted therapy related AEs (pulmonary lesion cavitation, pneumothorax, hair depigmentation) with the PFS

Measure: Early identification of AEs as predictive biomarker

Time: Baseline until disease progression or death, whichever occurs first, assessed for an average of 8 months

Other Outcomes

Description: The PFS for each subgroups in terms of clinicopathological characteristics (age, gender, histological type, solitary or multiple metastases, unilateral or bilateral metastases, early or late metastases, calcifying or non-calcifying lesions, with or without lesion cavitation, with or without AEs [especially pneumothorax, hand-foot skin reactions, hair depigmentation], etc

Measure: Exploratory outcome: Subgroup analysis of progression-free survival(PFS)

Time: Baseline until disease progression or death, whichever occurs first, assessed for an average of 8 months

Description: To explore the molecular basis underlying the difference of biomarker positive and negative sub-cohorts using next generation sequencing

Measure: Exploratory outcome: the molecular analysis of tumor sample

Time: through study completion, an average of 8 months

Description: to compare the growth pattern/ distribution of pulmonary versus extrapulmonary lesion at baseline and at disease progression between the two sub-cohorts

Measure: Exploratory outcome: the pattern of disease progression between the sub-cohorts

Time: Baseline until disease progression or death, whichever occurs first, assessed for an average of 8 months

Description: to compare the diagnostic value of the 1.0 mm versus 5.0 mm CT scan for the radiological evaluation of small lung nodule as tumor recurrence

Measure: Exploratory outcome: 1.0-mm CT scan for pulmonary assessment

Time: Baseline until disease progression or death, whichever occurs first, assessed for an average of 8 months


HPO Nodes


Sarcoma
Genes 197
REST RB1 SDHC KRAS PAX7 ABCA5 ASPSCR1 RECQL4 SUFU APC ANTXR2 FH GREM1 KRT17 EXT1 PIK3CA BMPR1B RASGRP1 KIT SDHD PRKCD REST KCNN3 IDH2 NF1 CTNNB1 PDGFRB CDKN2B KEAP1 DICER1 DICER1 TAF15 CDKN2A FGFR3 SLC22A18 PTCH2 CDKN2C NBN CHEK2 EP300 AXIN2 CHEK2 IFNG PTH1R COL1A1 FOXO1 TBX18 GJC2 FLT4 PRKAR1A DHCR24 MSH2 MLH1 ANTXR2 GNAS CASP10 TRIP13 NUTM1 MDM2 TSC1 PTEN KCNH1 BUB1B FLNA NF2 ELMO2 NF1 BUB3 DCC MEN1 TSC1 MSH2 TP53 PTEN FAM20C PDGFB BUB1 NOTCH3 ATP6V1B2 TSC1 SUFU FLCN WT1 MSH2 MEN1 FH NRAS MTAP APC NF1 CHEK2 NR4A3 NBN APC NF2 TSC2 IL6 SPRED1 AKT1 NRAS BUB1B SOS1 FLCN SDHC SMARCB1 IDH1 LMNA MSH6 SDHC TSC2 NF2 SRC BUB1 APC RECQL4 ABCA5 SDHB GNAS APC PDGFRB VEGFC HRAS KCNH1 FAS BRD4 PRLR DLC1 SDHB PIK3CA WRN TP53 MAP2K1 IDH1 BRAF MLH1 CDKN1A RPS19 FOXC2 EWSR1 PTCH1 APC AKT1 CDKN2A KIT TP53 PDGFB AKT1 MSH6 EWSR1 CDC73 KIT NRAS IDH2 EXT2 CDKN1B SOS1 NF1 KLLN APC TSC2 SSX2 SEC23B DICER1 PIK3CA PDGFRA FAS EXT1 APC RECQL4 HRAS MLH1 CTNNB1 BMPR1A PMS2 EXT2 WRN PTEN SSX1 SDHA PTPN11 SDHB BUB1B PAX3 FASLG GDF5 CEP57 SQSTM1 CDC73 EXT1 TP53 PTPRJ CDKN1B PLCD1 RB1 APC PTCH1 MC1R